Alumis Inc. (NASDAQ: ALMS) shares shot up 132% to $19.30 after the company said topline results from its Phase 3 ONWARD1 and ONWARD2 trials of envudeucitinib in moderate-to-severe plaque psoriasis met …
Dow Jumps Over 400 Points; US Services Activity Falls In December
view original post